Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

BMEA
Biomea Fusion, Inc. Common Stock
stock NASDAQ

At Close
Jul 31, 2026 3:59:50 PM EDT
1.17USD-3.689%(-0.05)469,991
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 31, 2026 8:31:30 AM EDT
1.24USD+1.639%(+0.02)280
After-hours
Jul 31, 2026 4:00:30 PM EDT
1.17USD-0.426%(0.00)19,413
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
08:37AM EST  Biomea Fusion Announces First Patient Dosed In BMF-219 Phase 1 Trial   Benzinga
08:30AM EST  -- BMF-219 is the first irreversible covalent menin inhibitor to enter the clinic -- Phase I trial is enrolling patients with relapsed/refractory acute leukemias, including those with MLL1/KMT2A gene rearrangements or NPM1 mutations -- Phase I trial is expected to include up to 20 clinical sites at leading US medical centers   GlobeNewswire Inc
Jan 12, 2022
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 12, 2022   Benzinga
06:13AM EST  HC Wainwright & Co. Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $13   Benzinga
Jan 11, 2022
08:30AM EST  Biomea Fusion Announces Participation at the H.C. Wainwright 2022   GlobeNewswire Inc
Jan 10, 2022
08:40AM EST  Biomea Fusion Says Plans to Initiate Clinical Studies To Dose Its Irreversible Covalent Menin Inhibitor In Up To Seven Different Cancer Indications And Diabetes In 2022   Benzinga
08:30AM EST  Biomea Fusion Announces 2022 Clinical Development Plan to Initiate   GlobeNewswire Inc
Jan 6, 2022
08:35AM EST  Biomea Fusion Releases Pre-Clinical Data With BMF-219 In Diabetes   Benzinga
Jan 4, 2022
01:30PM EST  Biomea Fusion, Inc. (Biomea) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with genetically defined cancers, announced that it has moved into new headquarters in Redwood City, at 900 Middlefield Road.   GlobeNewswire Inc
Dec 21, 2021
08:00AM EST  Biomea Fusion to Present at the 40th Annual J.P. Morgan Healthcare   GlobeNewswire Inc
Dec 17, 2021
10:18AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021   Benzinga
05:49AM EST  Oppenheimer Initiates Coverage On Biomea Fusion with Outperform Rating, Announces Price Target of $22   Benzinga
Dec 14, 2021
08:23AM EST  Biomea Fusion Reports Will Be Added To NASDAQ Biotech Index Monday, Dec. 20, 2021   Benzinga
08:00AM EST  Biomea Fusion to be added to NASDAQ Biotechnology Index   GlobeNewswire Inc
Nov 10, 2021
02:00PM EST  Biomea Fusion to Participate in Two Upcoming Investor Conferences   GlobeNewswire Inc
Nov 4, 2021
10:50AM EDT  Biomea Fusion Publishes Abstract For BMF-219 At American Society Of Hematology   Benzinga
Nov 3, 2021
09:19AM EDT  Biomea Fusion Q3 EPS $(0.43)   Benzinga
08:00AM EDT  Biomea Fusion Reports Third Quarter 2021 Financial Results and   GlobeNewswire Inc
Sep 22, 2021
07:45AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs   Benzinga
Sep 16, 2021
01:36PM EDT  Biomea Fusion Announces FDA Clearance Of Investigational New Drug Application For Irreversible Menin Inhibitor BMF-219   Benzinga
01:35PM EDT  Biomea Fusion Announces FDA Clearance of Investigational New Drug   GlobeNewswire Inc
01:33PM EDT  CORRECTION: Biomea Fusion Shares Halted On Code News Pending   Benzinga
Aug 26, 2021
05:12AM EDT  Biomea Fusion CEO Andrew Butler Reported Purchase of 24,000 Shares @ Avg Price of $13.20/Share in Form 4 Filing on Wednesday   Benzinga
Aug 21, 2021
02:07PM EDT  The Past Week's Notable Insider Buys Included AppLovin, Cricut, Biotechs And More   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
05:22AM EDT  Biomea Fusion CEO Butler Reported Purchase of 204,470 Shares @ Avg Price of $16.15/Share in Form 4 Filing on Thursday   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 11, 2021
04:34PM EDT  Biomea Fusion H1'21 Net Loss $14.3M   Benzinga
04:05PM EDT  Biomea Fusion Reports Second Quarter 2021 Financial Results and   GlobeNewswire Inc
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jun 28, 2021
07:10PM EDT  BIOMEA Fusion Strengthens its Executive Team with Appointment of   GlobeNewswire Inc
May 27, 2021
04:13PM EDT  Biomea Fusion Q1 EPS $(0.49) Down From $(0.05) YoY   Benzinga
04:05PM EDT  -- Received $167 million in aggregate gross proceeds inApril from initial public offering --   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 11, 2021
10:07AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021   Benzinga
07:47AM EDT  Jefferies Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $26   Benzinga
07:36AM EDT  JP Morgan Initiates Coverage On Biomea Fusion with Overweight Rating, Announces Price Target of $26   Benzinga
06:46AM EDT  Piper Sandler Initiates Coverage On Biomea Fusion with Overweight Rating, Announces Price Target of $27   Benzinga
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
04:05PM EDT  Biomea Announces Closing of Initial Public Offering   GlobeNewswire Inc
Apr 16, 2021
11:53AM EDT  Biomea Fusion Shares Open For Trade At $20; IPO Priced At $17/Share   Benzinga
Apr 15, 2021
10:33PM EDT  Biomea Announces Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC